



PRESS RELEASE

FOR IMMEDIATE RELEASE

**The Third Asia Summit on Global Health Opens Today  
Haitong International Acts as Strategic Partner for the Second Consecutive Year,  
Accelerating Healthcare Innovation and Investment Opportunities**

**Hong Kong, 17 May 2023** - The third Asia Summit on Global Health ("the Summit") co-organized by the Government of the Hong Kong Special Administrative Region ("HKSAR") and the Hong Kong Trade Development Council ("HKTDC") commenced today at the Hong Kong Convention and Exhibition Centre. With the theme "Reimagining the Future of Healthcare", the summit serves as a platform for healthcare officials, science and medical experts, investors and industry leaders from around the world to convene and collaborate. **Haitong International Securities Group ("Haitong International" or the Group; 665.HK), as the Strategic Partner of the Summit for the second time**, participated in various sessions on the first day of the summit, focusing on health innovation and investment trends to foster industry development and business opportunities.

**Mr John Lee, The Chief Executive of the HKSAR, Ms Yu Yanhong, Member of Leading Party Members' Group, National Health Commission of the PRC and Secretary of Leading Party Members' Group, National Administration of Traditional Chinese Medicine, Dr Tedros Adhanom Ghebreyesus, Director-General of World Health Organization and Mr Peter Lam, Chairman of HKTDC**, attended the Summit's opening session. In the opening remarks, Mr John Lee, Chief Executive of the HKSAR, said "Under the "one country, two systems" principle, Hong Kong is bestowed with unique advantage of having the strong support of national strategies, while maintaining unrivalled connectivity with the world. The National 14<sup>th</sup> Five-Year Plan supports Hong Kong's development as an international innovation and technology (I&T) hub, emphasizing such emerging disciplines in the country as life and health sciences. Hong Kong boasts a thriving biotech community, at the end of March, 56 pre-revenue biotech companies had listed here, raising nearly 15 billion US Dollars; and is one of the world's largest fundraising hub for biotech companies."

**Boosting Collaborations to Foster Industry Development and Investment Opportunities**

The Summit featured a series of panel discussions on the first day, shedding light on various critical topics. These discussions included new business spotlights of healthcare in Asia, the latest healthcare advancements and shifting investment landscape in China, and the Guangdong-Hong Kong-Macao Greater Bay Area as the powerhouse of healthcare innovation. Distinguished government officials, business leaders and industry key players joined the Summit. **Prof Lo Chung-mau, Secretary for Health of the HKSAR, Mr Victor Chu, Chairman & CEO of First Eastern Investment Group, Ms Roberta Lipson, Founder of United Family Healthcare, Prof Dennis Lo, President of Hong Kong Academy of Sciences, Sir Jonathan Symonds, Chair of GSK, Dr Wang Xingli, Chief Executive Officer of Shanghai Fosun Pharmaceutical (Group), Mr Tatsuo Yasunaga, Chair of the Board of Directors of Mitsui & Co and Ms Yu Wenxin, Principal Analyst of Pharmaceutical Industry of**



**Haitong International** participated in the Plenary Session: Reimagining the Future of Healthcare.

During the discussion, Ms Yu Wenxin said "From the 'New Medical Reform' in 2009, the 'Drug Administration Reform' in 2015 to the 'Medical Insurance Reform' in 2018, the healthcare industry in the Mainland is experiencing a rapid growth and is becoming one of the world-leading pharmaceutical R&D centers. China has a large population base, coupled with favourable national policies like Medical Insurance Reform, the growth rate of the medical and healthcare industry in the mainland is higher than that of the world. In addition, referring to Chapter 18A of the Listing Rules issued by the Stock Exchange of Hong Kong, it has attracted various start-ups to have global reach via Hong Kong's financing platform, therefore, the healthcare industry will have enormous investment opportunities in the future."

### **Exploring the Future of Start-Ups to Connect with Global Investors**

Haitong International is committed to promoting industry exchanges and creating development opportunities by actively connecting medical and healthcare project owners with global investors and business partners. A series of one-to-one meetings (either physical or online) were held at ASGH Deal-Making to facilitate business networking and expansion.

The InnoHealth Showcase is a dedicated exhibition area, comprising over 140 healthcare start-ups under four main areas including pharmaceutical, AI & digital health, medical device & diagnostics and community health & wellness, connects medical and healthcare startups with potential investors and partners from around the world. It provides a platform to explore business opportunities and discover innovative solutions in the industry. In the thematic session of the Summit – Project Pitching, **Ms Yu Wenxin, Principal Analyst of Pharmaceutical Industry of Haitong International**, served as an Investment Mentor. She engaged in a fireside chat with a private equity investment expert, discussing the development and future prospects of pharmaceutical start-ups. During the discussion, Ms Yu highlighted the potential investment and financing challenges faced by different types of start-ups.

### **Promoting Hong Kong as the Medical and Healthcare Hub in Asia**

Haitong International and HKTDC hosted a cocktail reception, which brought together the industry leaders, exhibitors and investors at the Summit to exchange ideas, explore collaborations and establish valuable business networks. **Dr Patrick Lau, Deputy Executive Director of HKTDC** and **Dr Lin Yong, Deputy Chairman & Chief Executive Officer of Haitong International** attended the ceremony, while **Mr Henry Shi, Executive Committee Member of Haitong International** delivered a speech, stating, "we are delighted to be the strategic partner of the Summit again and be invited to serve as one of the Investment Mentors in InnoHealth Showcase, promoting Hong Kong as the business hub for the medical and healthcare industry in Asia. Hong Kong is the world-leading biotechnology financing center, with new listing chapters by the Stock Exchange of Hong Kong, it creates new opportunities for biotech and specialist technology companies, supporting more potential companies to utilize the financing and industrial platform in Hong Kong to achieve healthcare innovation. As a Chinese investment bank rooted



in Hong Kong, Haitong International strives to serve as a bridge linking up the Chinese and overseas capital markets, by actively leveraging on its resource advantages in capital intermediary and information intermediary. We are committed to connect investment opportunities for potential companies, accelerating innovation and development of healthcare industry.”

On the second day of the Summit, a series of engaging online seminars will take place, focusing on various topics such as the latest development in biomedical research & commercialization in Guangdong-Hong Kong-Macao Greater Bay Area, emerging focal points in healthcare including digital maturity in health, and more. International Healthcare Week and Hong Kong International Medical and Healthcare Fair are held concurrently to cover the full chain of medical and healthcare industry, creating an all-round healthcare platform.

In addition, Haitong International’s equity research team and HKTDC Research jointly released a report titled "Future Prospects of Healthcare Industry in Mainland China and Hong Kong". This report has garnered significant attention and enquiries from industry players, investors and media. To view the full report, please visit: <https://www.asiasummitglobalhealth.com/conference/asgh/en/joint-research-paper>

- END -

#### **Disclaimer**

We, Haitong International Securities Group Limited ("Haitong International" or "HTI") have prepared this document/presentation ("Document") for information purpose only and for restricted circulation. We have based this Document on our internal information and information available to the public from sources we believe to be reliable. While we have taken all reasonable care in preparing this Document, we do not represent the information contained in this Document is accurate or complete and we accept no responsibility for errors of fact or for any opinion expressed in this Document.

Opinions, projections and estimates reflect our assessments as of the Document date and are subject to change. We have no obligation to notify you or anyone of any such change. You must make your own independent judgment with respect to any matter contained in this Document. Neither we nor any of our affiliates or our respective directors, officers or employees will be responsible for any losses or damages which any person may suffer or incur as a result of relying upon anything stated or omitted from this Document. This Document does not create any legally binding obligations on us and/or our affiliates.

Nothing contained in this Document is intended to constitute legal, tax, securities or investment advice of any product. No information contained in this Document constitutes an offer, or a solicitation to buy or sell any product of any type or to engage in any other transaction. You should not act or refrain from acting on the basis of any content included in this Document without seeking your own professional or investment advice. This disclaimer is available in both English and Chinese, if there is any discrepancy between the two versions, the English version shall apply and prevail.

#### **Haitong International Securities Group Limited**

Haitong International Securities Group Limited ("Haitong International"; Stock Code: 665.HK) is an international financial institution with established presence in Hong Kong and a rapidly expanding network across the globe. It strives to serve as a bridge linking up the Chinese and overseas capital markets. The parent company of Haitong International is Haitong Securities Co. Ltd ("Haitong Securities", Stock Code: 600837.SH; 6837.HK).



Haitong International is well positioned to serve corporate, institutional, as well as high-net worth clients worldwide. Its well-established financial services platform provides a full spectrum of financial offerings including private wealth management, corporate finance, asset management and global markets (key businesses include sales and trading of both equity and fixed income products, prime brokerage and risk management solutions, and research advisory) businesses. Haitong International possesses a sound risk management system that is in line with international standards. The company has been assigned a "BBB" long-term credit rating by Standard and Poor's. Haitong International is also a high performer in terms of ESG and corporate governance. It has been assigned "A" in ESG rating by MSCI and included in the FTSE4Good Index by FTSE Russell. Haitong International has a global financial servicing network covering the world's major capital markets including Hong Kong, Singapore, New York, London, Tokyo, Mumbai and Sydney, thereby making it a world-class Chinese financial institution with international competitiveness, systemic importance and brand influence.

For further information, please contact:

**Haitong International Securities Group Limited**

Jessica Au

Tel: (852) 2213 8588

Email: [jessica.sk.au@htisec.com](mailto:jessica.sk.au@htisec.com)

Ginny Kung

Tel: (852) 2213 8586

Email: [ginny.wy.kung@htisec.com](mailto:ginny.wy.kung@htisec.com)